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Living donor liver transplantation (LDLT) from hepatitis C virus (HCV )–positive donors into HCV-positive recipients is not 
established yet.(1) We report a case of combining 
direct antiviral agent (DAA) therapy and living 
liver donation from a donor with chronic HCV 
infection (genotype 3a) to a recipient with con-
genital chronic HCV infection (genotype 3a).
Case Report
ReCIpIeNt
The recipient, an 11-year-old female (body mass 
index [BMI]  =  20.1  kg/m2), underwent subtotal 
left pancreas resection with splenectomy and partial 
omentectomy due to a pseudopapillary pancreas tumor 
(PPT) in 2015. Because of synchronous and diffuse 
hepatic metastases, three transarterial chemoemboli-
zations were performed 2016, but with persistent liver 
metastases. After extended staging, no extrahepatic 
manifestation of the PPT was found. Because of irre-
sectability of the liver metastases, liver transplantation 
was indicated for complete tumor clearance.
DoNoR
Thirty-six-year-old female (mother) and daugh-
ter were noncitizens in the Eurotransplant region. 
Therefore, only LDLT was possible, and the mother 
was the only blood group match (BMI = 25.73 kg/m2, 
AB0 group 0, Rh+). Both donor and recipient had 
a chronic HCV infection. At initial evaluation, the 
Abbreviations: DAA, direct antiviral agent; HCV, hepatitis C virus; LDLT, living donor liver transplantation; PPT, pseudopapillary pancreas 
tumor; SVR, sustained virological response.
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mother had a serum viral load of 6.6  ×  106  U/mL. 
and liver biopsy revealed an interface hepatitis with 
70% steatosis hepatis (Figs. 1A and 2A). DAA ther-
apy with sofosbuvir 400  mg and velpatasvir 100  mg 
was initiated for 3 months. At reevaluation, the HCV 
viremia was cleared, and HCV remained undetectable. 
Furthermore, liver enzymes were normal and the liver 
biopsy showed a marked reduction of the steatosis 
FIg. 1. (A) Therapy timeline of the donor with LDLT evaluation, DAA therapy, re-LDLT evaluation, liver donation, and 12-week SVR 
control, with laboratory results and histology results. (B) Disease history and therapy overview of the recipient with initial diagnosis, initial 
surgical resection, and transarterial chemoembolization therapy, staging, LDLT, DAA therapy, and 12-week SVR control followed by 
1-year control with laboratory and histology results. Two-year computed tomography scan shows no tumor re-occurrence. Abbreviations: 
AP, alkaline phosphatase; Bili, bilirubin; CT, computed tomography; gGT, gamma-glutamyltransferase; GOT, glutamic oxaloacetic 
transaminase; GPT, glutamic pyruvic transaminase; INR, international normalized ratio; MRI, magnetic resonance imaging; PET, 
positron emission tomography; and RFA, radio frequency ablation.
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hepatis to 5% (Figs. 1A and 2B). Consequently, no 
contraindications for living liver donation were seen. 
One year after donation, liver enzymes and cholesta-
sis parameter in the donor were normal, as well as 




LDLT was performed using the left lobe (seg-
ment II/III/IV, 693 mL) with a graft-to-bodyweight 
ratio of 1.6%. At transplantation, the recipient had 
an HCV viral load of 2.8 × 106 IU/mL. Seven weeks 
after transplantation, the volume of the graft increased 
to 1,221 mL or 91%. The HCV viral load reached its 
maximum of 180 × 106 IU/mL 1 month after trans-
plantation. Two months later, the recipient had an 
HCV load of 1.5  ×  106  IU/mL. DAA therapy was 
now initiated with sofosbuvir 400  mg and velpat-
asvir 100  mg for 12  weeks. During the DAA ther-
apy a liver biopsy was performed for elevated liver 
enzymes; it revealed no signs of rejection but a 60% 
steatosis hepatis (Figs. 1B and 2C). After the DAA 
therapy, HCV viremia was cleared with a sustained 
viral response by week 12, and HCV remained unde-
tectable thereafter. The 1-year protocol biopsy showed 
a marked reduction of steatosis hepatis to 20% and 
no signs of chronic liver injury (Fig. 2D). An abdom-
inal magnetic resonance imaging scan 1 year after, 
and a computed tomography scan 2  years after, the 
transplantation showed no signs of tumor recurrence, 
neither in the bed of pancreatic resection nor in the 
transplanted liver.
Discussion
In the presented case, liver transplantation was 
indicated, as 85%-95% of patients with PPT are 
cured after complete tumor clearance, and success-
ful liver transplantation for metastatic PPT has been 
reported.(2) In the era of highly effective DAAs, graft 
survival among HCV-positive recipients has largely 
increased, with outcomes comparable to non–HCV-
positive recipients.(3)
FIg. 2. Liver-biopsy hematoxylin and eosin staining. (A) Donor before DAA therapy with chronic, mostly portal, but discrete interface 
hepatitis with a severe steatosis hepatis and mild fibrosis (1-2 Ishak score). (B) Donor after DAA therapy with only minimal steatosis 
hepatis and stable mild periportal fibrosis. (C) Recipient under DAA therapy also shows severe steatosis hepatis and mild fibrosis. 
(D) Recipient 1-year protocol biopsy with reduced steatosis hepatis.
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However, little is known about living donors with 
chronic HCV infection. Here, once HCV remains 
undetectable in the donor, the liver recovers quickly 
from the steatosis, and living liver donation could be 
performed without reoccurrence of HCV after dona-
tion. To monitor steatosis, we recommend an eval-
uation biopsy of the donor. LDLT was done before 
the donor sustained virological response 12 (SVR12), 
due to risk of extrahepatic tumor manifestation in the 
recipient. If the recipient is able to wait for the donor 
SVR12, we recommend this for donor risk reduction.
DAA therapy of the recipient was performed suc-
cessfully after LDLT, due to unknown possible effects 
of the DAA therapy on the tumor biology and tumor 
growth of this rare tumor type. Nevertheless, now, 
2  years after LDLT, HCV remains undetectable and 
the liver function of the recipient is normal and with-
out signs of tumor recurrence.
Even if a single case does not allow definitive con-
clusion, the concept of antiviral DAA therapy in com-
bination with LDLT in HCV-infected donors and 
recipients should be considered to increase the donor 
pool in this highly selective population. The optimal 
timing for treatment of the pediatric recipient (before 
or after transplantation) remains to be clarified.
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